Focus on CNS Pharma deals: How to pull in the money

Best Practices - Focus on CNS Pharma deals: “How to pull in the money “

[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],OUTLINE

Company Overview ,[object Object],[object Object],[object Object],[object Object],[object Object],SHI LINK

Both pharma and biotech face the same challenges ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],LICENSING DRIVERS DM Report, 05/06. Both pharma and biotech face the same development challenges Biotech’s strengths Pharma’s strengths Novel products and technology Financial strength Differentiated products Development, sales and marketing expertise Entrepreneurial business culture Global positioning and reputation Creativity Larger share of voice

Both pharma and biotech face the same challenges ,[object Object],[object Object],[object Object],LICENSING DRIVERS DM Report, 05/06. Drivers of licensing are increasingly outweighing resistors Licensee Licensor Resistors Drivers ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Both pharma and biotech face the same challenges ,[object Object],[object Object],[object Object],[object Object],LICENSING DRIVERS Competition for products drives up cost of licensing deals Increased preclinical licensing in recent years DM Report, 05/06.

CNS remains one of the highest revenue generators in mid and big pharma ,[object Object],[object Object],CNS DEALS DM Report, 05/06. % of total peer set revenue Big Pharma Mid Pharma Mid Pharma and Big Pharma therapy area split

Hot area – total number of deals ,[object Object],[object Object],CNS DEALS Number of deals Deal types since January 2006 The majority of clinical CNS deals involve PII candidates Licensing deals comprise ~ half of the total CNS transactions Windhover, 2007.

Hot area – total number of deals ,[object Object],[object Object],CNS DEALS Number of deals Disclosed value of CNS deals (since Jan 2006) Small CNS deals predominate Windhover, 2007.

Hot area – total number of deals CNS DEALS Profile of some larger CNS deals Windhover, 2007. UF: $35 M MS: $100 M + $1B in discovery, development and regulatory MS $1.035 B USD Targacept licenses GSK’s Center of Excellence for External Drug Discovery rights to two neuronal nicotinic receptor (NNR) modulators July 1 2007 GSK-Targacept UF: $75 M MS: $275 M $350 M USD Xenoport licenses GSK exclusive WW rights to develop, manufacture and market XP 13512 (PIII restless leg, PII neuropathic pain) Feb 1 2007 GSK-XenoPort UF:$40 M MS:$345M $385 M USD Takeda and H. Lundbeck will exclusively co-develop/ promote several of Lundbeck’s neurology candidates in the US and Japan Sept 1 2007 Takeda-H. Lundbeck UF: $250 M MS: $750 M $1B USD Development and marketing of BMS’s PIII anticoagulant apixaban April 1 2007 BMS-Pfizer Deal terms Potential Deal Value Deal Title Date Companies

SHI Link provides commercial strategy, execution & network support ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],SHI LINK

Gardiner Smith: Transactional Experience CNS DEALS

SHI Link – Philadelphia 109 N. Orianna Street Philadelphia, PA 19106 (215) 923-8200 SHI Link – Toronto #310 – 162 Cumberland Street Toronto, ON M5N 3R5 (416) 236-1054 www.shilink.com

We deliver a win/win compensation structure ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],ENGAGEMENT

We assist in understanding the strategic value of assets ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],ASSET EVALUATION

Our goal is to assist you in getting to signature quickly ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],EXECUTION

We understand both sides of the equation ,[object Object],[object Object],[object Object],[object Object],ENGAGEMENTS CASE STUDY #2 CHALLENGE: An oncology company was seeking input on the business development strategy for its lead Phase I product. APPROACH: SHI Link evaluated the product and determined that the mechanism of action is amenable to a drug/device combination product. This strategy enables the company to obtain a partnership at an early stage of clinical development while continuing to develop its lead program for future out-licensing. IMPACT: SHI Link is currently engaged in out-licensing the oncology product to a medical device company. CASE STUDY #3 CHALLENGE: A public, mid-size biopharma company is seeking to in-license a Phase III product to bridge future revenue gaps. APPROACH: SHI Link created databases in two therapeutic areas and is also assisting in negotiations and term sheet creation. IMPACT: SHI Link is currently assisting the client in several ongoing deals.

A team with proven executive track records PRINCIPALS ,[object Object],[object Object],[object Object],[object Object]

[object Object],[object Object],[object Object],[object Object],DEAL DETAILS

Focus on CNS Pharma deals: How to pull in the money

Recomendados

Recomendados

Mais conteúdo relacionado

Mais de MaRS Discovery District

Mais de MaRS Discovery District (20)

Último

Último (20)

Focus on CNS Pharma deals: How to pull in the money